Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2024-05-20 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
毕马威华振会计师事务所 (特殊普通合伙) 关于深圳微芯生物科技股份有限公司2023年年度报告的信息披露监管问询函专项回复说明
Annual Report Classification · 95% confidence The document is a detailed response to a regulatory inquiry from the Shanghai Stock Exchange regarding the 2023 annual report of Shenzhen Microchip Biotechnology Co., Ltd. It includes extensive discussion of the company's audited financial statements for the year ended December 31, 2023, issued by KPMG Huazhen, including balance sheets, profit and loss statements, cash flow statements, and notes. The document addresses accounting standards related to consolidation and control, detailed explanations about subsidiary disposal, shareholding structures, board composition, and financial data for 2023. The presence of an audit report with an unqualified opinion dated March 28, 2024, and the detailed financial and operational disclosures indicate this is part of the official annual report filing. The document is substantive, over 15,000 characters, and contains actual financial data and management explanations, not merely an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2023
2024-05-20 Chinese
关于2023年年度报告信息披露监管问询函的回复公告
Audit Report / Information Classification · 95% confidence The document is a detailed response to a regulatory inquiry regarding the company's 2023 Annual Report, specifically addressing issues related to the disposal of a subsidiary and the accounting treatment thereof. It references the 2023 Annual Report multiple times, discusses financial data for 2023, compliance with accounting standards, and detailed explanations of control and consolidation accounting. The document is lengthy (15,000 characters) and contains substantive financial and operational information, not merely an announcement or certification. It is clearly a regulatory inquiry response related to the annual report, which fits the category of Audit Report / Information (AR) because it is a standalone audit-related disclosure and explanation, not the full Annual Report (10-K) itself. It is not a simple announcement or a certification letter, nor is it a general regulatory filing. Therefore, the best classification is AR with high confidence. FY 2023
2024-05-20 Chinese
自愿披露关于西达本胺治疗结直肠癌III临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the acceptance of a Phase III clinical trial application for a new drug by the National Medical Products Administration (NMPA) in China. It contains no financial statements or detailed financial data. It is an official announcement about regulatory acceptance of a clinical trial application, which is a regulatory update rather than a financial report or management discussion. The document length is short (1657 characters), and it does not contain or reference any financial report or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-05-12 Chinese
关于“微芯转债”回售结果的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the results of a convertible bond (可转债) repurchase (回售) by Shenzhen Microchip Biotechnology Co., Ltd. It details the repurchase period, the number of bonds tendered (0), the repurchase amount (0), and the impact on the company. It references prior announcements about the repurchase and states that the bonds will continue trading as no repurchase occurred. The document is short (1243 characters) and focuses on the outcome of a financing-related event (convertible bond repurchase). This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. It is not a full financial report, earnings release, or regulatory filing. Therefore, the correct classification is CAP with high confidence.
2024-05-12 Chinese
关于“微芯转债”可选择回售的第三次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the third reminder for the optional repurchase (回售) of its convertible bonds (微芯转债). It details the repurchase price, repurchase period, payment date, and procedures for bondholders to exercise their repurchase rights. The document includes legal disclaimers, references to regulatory rules, and specific dates related to the bond repurchase. It does not contain financial statements, earnings data, or management discussion but is clearly an update on a capital market event related to convertible bonds. This fits the category of Capital/Financing Update (CAP), as it concerns financing activities and capital structure changes (bond repurchase option). The document length is short (2111 characters), but it is not merely an announcement of a report publication; it contains substantive information about the repurchase terms and procedures.
2024-05-06 Chinese
自愿披露关于西达本胺联合R-CHOP治疗弥漫大B细胞淋巴瘤适应症获批上市的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval and market launch of a new drug indication by the National Medical Products Administration (国家药品监督管理局). It details the drug's registration certificate, clinical trial results, and potential impact on the company's business. The document is relatively short (1581 characters) and serves as a formal public disclosure of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-04-30 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.